Cardiovascular disease after liver transplantation: When, what, and who is at risk

Liver Transplantation

Volumn 21, Issue 7, 2015, Pages 889-896

  Fussner, Lynn A ^a   Heimbach, Julie K ^a   Fan, Chun ^a   Dierkhising, Ross ^a   Coss, Elizabeth ^a   Leise, Michael D ^a   Watt, Kymberly D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; BIOLOGICAL MARKER; CYCLOSPORIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FERRITIN BLOOD LEVEL; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; ADVERSE EFFECTS; BODY MASS; COMORBIDITY; COMPLICATION; END STAGE LIVER DISEASE; INCIDENCE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COMORBIDITY; CYCLOSPORINE; DIABETES COMPLICATIONS; END STAGE LIVER DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; INCIDENCE; LIVER TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS;

EID: 84933512267     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24137     Document Type: Article

References (21)

1. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J,. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
2. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
3. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al., Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114.
4. Watt KD, Coss E, Pedersen RA, Dierkhising R, Heimbach JK, Charlton MR,. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl 2010; 16: 990-998.
5. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for Mortality post-liver transplant: results of the NIDDK long term follow-up study. Am J Transplant 2010; 10: 1420-1427.
6. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS,. Prediction of cardiac complications after liver transplantation. Transplantation 2009; 87: 763-770.
7. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, Mahenthiran J,. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation 2009; 120: 1189-1194.
8. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR,. Predictors of cardiovascular events after liver transplantation: a role for pre-transplant serum troponin levels. Liver Transpl 2011; 17: 23-31.
9. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al., Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-643.
10. Braun S, Ndrepepa G, von Beckerath N, Vogt W, Schömig A, Kastrati A,. Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis 2004; 174: 105-110.
11. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, et al., Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 2015; 65: 45-53.
12. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al.,; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
13. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M,. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654.
14. Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, Krom RA,. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg 1998; 4: 328-334.
15. Seibert F, Behrendt C, Schmidt S, van der Giet M, Zidek W, Westhoff TH,. Differential effects of cyclosporine and tacrolimus on arterial function. Transpl Int 2011; 24: 708-715.
16. Rouyer O, Talha S, Di Marco P, Ellero B, Doutreleau S, Diemunsch P, et al., Lack of endothelial dysfunction in patients under tacrolimus after orthotopic liver transplantation. Clin Transplant 2009; 23: 897-903.
17. Tepperman ED, Tumiati LC, Ramzy D, Badiwala MV, Sheshgiri R, Prodger JL, et al., Tacrolimus preserves vasomotor function and maintains vascular homeostasis. J Heart Lung Transplant 2011; 30: 583-588.
18. Gadano A, Hadengue A, Widmann JJ, Vachiery F, Moreau R, Yang S, et al., Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology 1995; 22: 458-465.
19. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, et al., Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999; 30: 58-64.
20. Ford ES, Giles WH, Mokdad AH,. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449.
21. Richards J, Gunson B, Johnson J, Neuberger J,. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466.